Bevacizumab (Avastin, Roche, Basel, Switzerland) is a recombinant humanized monoclonal antibody against vascular endothelial growth factor that was developed originally to treat metastatic carcinoma of the colon and rectum. 1 Because it was designed to be used systemically, Michels and colleagues used off-label bevacizumab intravenous infusions to treat neovascular age-related macular degeneration (AMD). 2 After the efficacy of intravenous bevacizumab on AMD was proved, it was administered intravitreally, 3, 4 and injection of intravitreous bevacizumab (IVB) began to be used widely for treatment of various ocular diseases, including branch retinal vein occlusion (BRVO), 5, 6 polypoidal choroidal vasculopathy (PCV), 7, 8 retinal angiomatous proliferation (RAP), 9 , 10 myopic choroidal neovascularization (CNV), 11, 12 CNV secondary to angioid streaks (AS), 13, 14 proliferative diabetic retinopathy, 15, 16 and neovascular glaucoma. 17, 18 IVB can cause complications, including traumatic cataract, retinal detachment, and endophthalmitis, with the reported incidence of endophthalmitis ranging from 0.014% to 0.082%. [19] [20] [21] [22] [23] [24] Although several cases of sterile endophthalmitis have been reported, most of these cases have been sporadic and in most instances the inflammation subsided with no treatment or with topical treatment. 4, [25] [26] [27] In late December 2008, Genentech issued a letter informing ophthalmologists about 36 cases of intraocular adverse reactions following the off-label use of intravitreal bevacizumab. Most cases that have been reported occurred in patients who received intravitreal bevacizumab from a single batch.
However, the precise ocular symptoms, reaction to the treatment, and visual prognosis have not been reported.
In the present study, we describe 14 consecutive cases of sterile endophthalmitis after injection of IVB, some of which required pars plana vitrectomy. Each of these 14 eyes was treated with bevacizumab that originated from a single batch.
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Results
Ocular inflammation occurred in 14 eyes of 11 patients a few days after IVB injection (Tables 1 and 2 ), while the other 5 eyes did not show any inflammatory sign after receiving the IVB. The vitreous opacity became so dense that the optic disc could be observed only barely in 5 eyes, which were classified as the "severe inflammation" group; the other 11 eyes with inflammation were classified as the "moderate inflammation" group. The 5 eyes without inflammation were classified as the "no inflammation" group.
In eyes with severe ocular inflammation, the patients complained of eye pain and moderate conjunctival hyperemia. Slitlamp examination revealed moderate to severe cellular infiltration in the anterior chamber and vitreous cavity; three eyes showed hypopyon. The vitreous opacity became extensively dense in spite of intravenous antibiotics (imipenem), and visual acuity declined to count fingers in two eyes, to 2.0 in logMAR in two eyes, and to 1.5 in logMAR in one eye. These five eyes with severe ocular inflammation underwent pars plana vitrectomy (PPV) with instillation of intravitreal antibiotics (vancomycin and ceftazidime) on the third day; a sample of aqueous humor and vitreous was collected for culture. These cultures were all negative for Gram-positive bacteria, Gram-negative bacteria, and fungi.
Eyes with moderate ocular inflammation were treated with topical antibiotics (gatifloxacin and cefmenoxime) with or without a topical steroid Sterile Endophthalmitis after Bevacizumab. Yamashiro K, et al. Page 9 (betamethasone). In the two eyes with moderate vitreous opacity, systemic antibiotics (cefotiam) and a steroid (predonizolone) were added to the topical treatment. The inflammatory reaction in the anterior segment subsided within one week and the vitreous opacity subsided within a month. Some of the eyes thought to have no inflammation were not examined for several days after having been seen on the day after IVB injection, so ocular inflammation may have been present for a few days, without consultation, in these eyes.
Each patient was followed-up for at least one month after IVB treatment.
Visual acuity was unchanged from pretreatment levels in 17 eyes but declined in 2 ( Figure) ; it was restored to the level before IVB injection in the "no inflammation" group and in the "moderate inflammation" group, but declined in two eyes in the "severe inflammation" group.
A previous intravitreal injection of bevacizumab had been given 0.80 ± 0.84 times in the "no inflammation" group, 1.67 ± 1.87 times in the "moderate inflammation" group, and 2.20 ± 2.17 times in the "severe inflammation" group, so there was no significant difference in the frequency of a prior IVB injection (P = 0.46). Furthermore, there was no significant difference when the experience was compared among the three groups: two eyes without prior IVB and three eyes with prior IVB in the "no inflammation" group, four eyes without prior IVB and five eyes with prior IVB in the "moderate inflammation" group, and one eye without prior IVB and four eyes with prior IVB in the "severe inflammation" group.
No inflammatory reaction was detected after any of these previous IVB Sterile Endophthalmitis after Bevacizumab. Yamashiro K, et al. Page 10 injections.
Cataract surgery had been performed in one eye (20%) in the "no inflammation" group, in three eyes (33%) in the"moderate inflammation" group, and in four eyes (80%) in the "severe inflammation" group, so there was no statistically significant difference in the lens status between the groups. 
Discussion
The present study consists of 14 consecutive cases of endophthalmitis after intravitreal injection of bevacizumab that had been derived from a single batch. Because cultures of the aqueous humor and vitreous from five eyes with severe endophthalmitis were negative for bacteria and fungi, these eyes were believed to have a sterile endophthalmitis. Except for two eyes with severe endophthalmitis, the visual acuity returned to that measured initially. Although it is possible that inflammatory signs were not seen in those patients who did not return to the hospital for several days after examination on the day immediately after that of IVB injection, for analysis we classified the 19 cases in the present study into one of three groups: "no inflammation", "moderate inflammation", and However, no patient in the present study had a history of uveitis. Pseudophakia is also a risk factor for sterile endophthalmitis after IVTA, 29 but, because the lens status was not different among the three groups (i.e., "no inflammation", Sterile Endophthalmitis after Bevacizumab. Yamashiro K, et al. Page 13 "moderate inflammation", and "severe inflammation"), this was not a risk factor for ocular inflammation after injection of IVB in the present study.
Because bevacizumab is a full-length humanized IgG antibody, repeated injection might increase the risk of sterile endophthalmitis. However, in the study described herein, prior IVB did not affect the severity of ocular 
Figure Legend
Visual acuity in logMAR immediately before intravitreal injection of bevacizumab (x-axis) and at the final examination one month after the injection (y-axis).
Circles indicate eyes without ocular inflammation; triangles indicate eyes with moderate inflammation; reversed triangles indicate eyes with ocular inflammation severe enough to require pars plana vitrectomy. 
